Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
42.8M
-
Shares change
-
+1.1M
-
Total reported value, excl. options
-
$3.6B
-
Value change
-
+$96.2M
-
Put/Call ratio
-
0.15
-
Number of buys
-
84
-
Number of sells
-
-43
-
Price
-
$84.06
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q4 2021
153 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q4 2021.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.8M shares
of 72.2M outstanding shares and own 59.33% of the company stock.
Largest 10 shareholders include FMR LLC (6.8M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.38M shares), Matrix Capital Management Company, LP (4.35M shares), VANGUARD GROUP INC (3.19M shares), BlackRock Inc. (2.84M shares), Avidity Partners Management LP (2.72M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.63M shares), VIKING GLOBAL INVESTORS LP (2.12M shares), STATE STREET CORP (1.35M shares), and PRIMECAP MANAGEMENT CO/CA/ (1.25M shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.